Showing 20 of 91 recruiting trials for “myelodysplastic-syndrome”
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
👨⚕️ Jianxiang Wang, MS, The Haematology Hospital of the Chinese Academy of Medical Sciences📍 3 sites📅 Started Apr 2025View details ↗
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
👨⚕️ Chief Medical Officer, MD, MSc, MBA, Solu Therapeutics📍 7 sites📅 Started Mar 2025View details ↗
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
👨⚕️ Guillaume Richard-Carpentier, University Health Network Princess Margaret Cancer Center LAO📍 5 sites📅 Started Mar 2025View details ↗
Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
🏥 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Nov 2024View details ↗
RecruitingNCT06692894 ↗
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
👨⚕️ Somedeb Ball, MD, Vanderbilt University/Ingram Cancer Center📍 1 site📅 Started Aug 2024View details ↗
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
👨⚕️ Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06377579 ↗
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
👨⚕️ Pierre PETERLIN, Dr, French Innovative Leukemia Organisation📍 21 sites📅 Started Jul 2024View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →